- Home
- GDL vs ECOR Comparison
GDL vs ECOR Comparison
Compare GDL & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ECOR
- Stock Information
- Founded
- GDL 2006
- ECOR 2005
- Country
- GDL United States
- ECOR United States
- Employees
- GDL N/A
- ECOR N/A
- Industry
- GDL Investment Managers
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GDL Finance
- ECOR Health Care
- Exchange
- GDL Nasdaq
- ECOR Nasdaq
- Market Cap
- GDL 94.9M
- ECOR 111.3M
- IPO Year
- GDL N/A
- ECOR 2018
- Fundamental
- Price
- GDL $8.15
- ECOR $15.90
- Analyst Decision
- GDL
- ECOR Strong Buy
- Analyst Count
- GDL 0
- ECOR 1
- Target Price
- GDL N/A
- ECOR $25.00
- AVG Volume (30 Days)
- GDL 11.2K
- ECOR 144.8K
- Earning Date
- GDL 01-01-0001
- ECOR 03-12-2025
- Dividend Yield
- GDL 6.02%
- ECOR N/A
- EPS Growth
- GDL N/A
- ECOR N/A
- EPS
- GDL N/A
- ECOR N/A
- Revenue
- GDL N/A
- ECOR $23,327,000.00
- Revenue This Year
- GDL N/A
- ECOR $59.81
- Revenue Next Year
- GDL N/A
- ECOR $38.49
- P/E Ratio
- GDL N/A
- ECOR N/A
- Revenue Growth
- GDL N/A
- ECOR 74.10
- 52 Week Low
- GDL $7.65
- ECOR $5.32
- 52 Week High
- GDL $8.13
- ECOR $18.67
- Technical
- Relative Strength Index (RSI)
- GDL 59.30
- ECOR 53.73
- Support Level
- GDL $8.12
- ECOR $15.50
- Resistance Level
- GDL $8.17
- ECOR $16.12
- Average True Range (ATR)
- GDL 0.06
- ECOR 1.20
- MACD
- GDL 0.01
- ECOR -0.31
- Stochastic Oscillator
- GDL 89.47
- ECOR 40.17
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.